Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Whole Body Bone Scan Clear all
Recruiting Not applicable Interventional Accepts healthy volunteers

CArdioMEtabolic Function and Reserve Capacity in Healthy Adults: The CAMERA Study

NCT06220396
View directory record Official record
Conditions
Healthy
Interventions
Right Heart Catheterization with Hemodynamics and Limited Echocardiogram, Magnetic Resonance Imaging (MRI), Dual X-ray absorptiometry (DEXA) scan
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
30 Years and older
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Results available

Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy

NCT03388619
View directory record Official record
Conditions
Cancer Of Prostate, Prostate Neoplasms, Prostate Cancer, Neoplasms of Prostate, Prostatic Cancer
Interventions
Prostate bed with integrated boost, Prostate bed irradiation only, Whole Body Bone Scan, 18F-NaF PET Imaging, CT, mpMRI, ADT
Radiation · Diagnostic Test · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases

NCT00375830
View directory record Official record
Conditions
Cancer
Interventions
Bone scan, 99mTc-methyl diphosphonate, Positron Emission Tomography (PET) scan, 18F-Fludeoxyglucose (18F-FDG), Computed Tomography (CT) scan, 18F-Sodium Fluoride (18F-NaF), Whole Body Magnetic Resonance Imaging (WB-MRI) scan, Gadopentetate dimeglumine, Gadofosveset, Gadobutrol
Procedure · Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2019
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2023 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational

Bladder and Bone Effects of Pelvic Radiation Therapy in Childhood Cancer Survivors

NCT05818462
View directory record Official record
Conditions
Cancer, Childhood Cancer
Interventions
Uroflow testing, Bladder Scan, Dysfunctional Voiding Scoring System Survey, DEXA Scan of pelvis and sacral spine, Urine tests for specific biomarkers
Diagnostic Test · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

BrUOG L301 With Non-Small Cell Lung Cancer and Bone Metastases

NCT02283749
View directory record Official record
Conditions
Non Small Cell Lung Cancer With Bone Metastatses
Interventions
Xofigo
Biological
Lead sponsor
Angela Taber MD
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Microarchitecture at the Radius: a Pilot Comparison Between Children With Cystic Fibrosis and Healthy Controls

NCT01331980
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Peripheral quantitative computed tomography (pQCT), Dual X-ray absorptiometry (DXA)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
6 Years to 12 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 2, 2015 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational

Body Composition During Cancer Treatment

NCT03784911
View directory record Official record
Conditions
Cancer
Interventions
SOZO Device, DEXA Scan
Device
Lead sponsor
Prisma Health-Upstate
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Greenville, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 27, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Not applicable Interventional

Proton Craniospinal Irradiation With Bone Sparing to Decrease Growth Decrement From Radiation

NCT03281889
View directory record Official record
Conditions
Brain Tumor
Interventions
Proton Beam
Radiation
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
3 Years to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Not yet recruiting Early Phase 1 Interventional

Chemical-Shift-Encoded MRI for Active Bone Marrow Dosimetry in Radiopharmaceutical Therapy

NCT07609225
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

Intratreatment FDG-PET During Radiation Therapy for Gynecologic and Gastrointestinal Cancers

NCT03403465
View directory record Official record
Conditions
Cancer of the Cervix, Vulvar Cancer, Esophageal Cancer, Anal Canal Cancer
Interventions
FDG PET scan
Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Not applicable Interventional

Radiotherapy Dose De-escalation in HPV-Associated Cancers of the Oropharynx

NCT04667585
View directory record Official record
Conditions
Oropharynx Cancer
Interventions
De-escalated radiation dose, Standard radiation dose, 18 fluorodeoxyglucose (FDG)-positron emission tomography (PET)-Computed Tomography (CT)
Radiation · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
2
States / cities
Durham, North Carolina • Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

NCT06252675
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Obinutuzumab, Glofitamab, Pirtobrutinib, Tumor Imaging, Biospecimen Collection, ClonoSeq Assay, Bone Marrow Biopsy
Biological · Drug · Procedure + 1 more
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
3
States / cities
Davis, California • Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Inflammation, Diabetes, Ethnicity and Obesity Cohort

NCT03022682
View directory record Official record
Conditions
Obesity, Diabetes Mellitus, Pre Diabetes
Interventions
Not listed
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations

NCT06906562
View directory record Official record
Conditions
Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Pemigatinib, Computed Tomography (CT), Magnetic Resonance Imaging, Optical Coherence Tomography, Bone Scan, Ophthalmoscopy
Drug · Procedure
Lead sponsor
Sameek Roychowdhury
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
109
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 106 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 2 Interventional

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

NCT07046078
View directory record Official record
Conditions
Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Cytarabine, Echocardiography Test, Fludarabine, Idarubicin, Multigated Acquisition Scan, Peripheral Blood Stem Cell, Questionnaire Administration, Recombinant Granulocyte Colony-Stimulating Factor, Total-Body Irradiation
Procedure · Drug · Biological + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Not applicable Interventional

Bone Mineral Density Precision Study

NCT06830811
View directory record Official record
Conditions
Indicated for EOSedge Imaging
Interventions
EOSedge imaging
Radiation
Lead sponsor
Alphatec Spine, Inc.
Industry
Eligibility
20 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Fishers, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional

CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia

NCT04375631
View directory record Official record
Conditions
Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia
Interventions
Cladribine, Cyclophosphamide, Cyclosporine, Cytarabine, Filgrastim, Hematopoietic Cell Transplantation, Mitoxantrone, Mycophenolate Mofetil, Mycophenolate Sodium, Total-Body Irradiation, Idarubicin, Fludarabine, Multigated Acquisition Scan, Echocardiography Test, X-Ray Imaging, Bone Marrow Biopsy, Bone Marrow Aspiration, Biospecimen Collection
Drug · Biological · Procedure + 1 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Validation of FACBC for Detection of Metastasis Among High-risk Prostate Cancer Patients With Presumed Localized Disease

NCT03081884
View directory record Official record
Conditions
Cancer
Interventions
FACBC PET-CT Imaging
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older · Male only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 24, 2021 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional

Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

NCT04994808
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
Clofarabine, Fludarabine, Hematopoietic Cell Transplantation, Total-Body Irradiation, Treosulfan, Echocardiography Test, Multigated Acquisition Scan, Lumbar Puncture, Bone Marrow Aspiration, Bone Marrow Biopsy, Biospecimen Collection
Drug · Procedure · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Skeletal Health and Bone Marrow Composition Among Youth

NCT04203381
View directory record Official record
Conditions
Gender Dysphoria in Children, Puberty, Bone Development
Interventions
GnRH Agonist
Device
Lead sponsor
Amy DiVasta, MD
Other
Eligibility
9 Years to 14 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Phase 1/2 Study of Intravenous Gene Transfer With an AAV9 Vector Expressing Human Beta-galactosidase in Type I and Type II GM1 Gangliosidosis

NCT03952637
View directory record Official record
Conditions
Lysosomal Diseases, Gangliosidosis, GM1
Interventions
AAV9-GLB1, Abdominal ultrasound, Rituximab, Sirolimus, Methylprednisolone, Prednisone, Audiology assessment with ABR, Bone density scan (DEXA), Electrocardiogram (EKG), Echocardiogram, Electroencephalogram (EEG) awake and extended overnight, Laboratory tests, Lumbar puncture, Brain MRI/MRS/fMRI, Neurocognitive testing, Neurology exam, PICC or other Central line placement, Skeletal survey, Skin biopsy, Speech and modified barium swallow study, Ophthalmology exam
Biological · Procedure · Drug + 3 more
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
6 Months to 12 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 20, 2026 · Synced Sep 25, 2026, 10:15 AM EDT
Completed Not applicable Interventional Results available

Fluorine F 18 Sodium Fluoride PET/CT and Whole Body and Axial MRI in Finding Metastases in Patients With Recurrent Prostate Cancer

NCT01967862
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
computed tomography, bone scan, 3-Tesla magnetic resonance imaging, diffusion-weighted magnetic resonance imaging, fluorine F 18 sodium fluoride, positron emission tomography, laboratory biomarker analysis
Procedure · Radiation · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
2
States / cities
Duarte, California • South Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Sep 25, 2026, 10:15 AM EDT
Completed No phase listed Observational

Bone Mineral Density Status in Pediatric and Adolescent Survivors of Childhood Cancer With History of Bone Fracture

NCT02355340
View directory record Official record
Conditions
Bone Mineral Density, Childhood Cancer Survivors
Interventions
Dual energy x-ray absorptiometry (DXA), Peripheral quantitative computed tomography (pQCT)
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
8 Years to 20 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2024
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 5, 2024 · Synced Sep 25, 2026, 10:15 AM EDT
Active, not recruiting Phase 2 Interventional

Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

NCT06752694
View directory record Official record
Conditions
Aplastic Anemia
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Marrow Transplantation, Computed Tomography, Cyclosporine, Fludarabine, Granulocyte Colony-Stimulating Factor, Mycophenolate Mofetil, Peripheral Blood Stem Cell Transplantation, Ruxolitinib, Sirolimus, Total-Body Irradiation, Multigated Acquisition Scan, Echocardiography
Procedure · Drug · Radiation
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 25, 2026, 10:15 AM EDT